Yselty For Uterine Fibroids Edges Closer To Being Obseva’s First Commercial Product

 
• By Jessica Merrill

Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.

Numbers on red running track. Start and Finish point of a race track in a stadium
ObsEsva is looking to join a competitive women's health category • Source: Shutterstock

More from Immunological

More from Therapy Areas